RxDoctor Payments Data

Erin Taylor

Family · Harvey, LANPI 1457927212

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Lilly USA, LLC at 27.3% of the total. Reporting peaked in 2023 at $934 and has fallen 83.2% since, to $157 in 2025.

$2,029in general payments, 2019–2025

Across 72 payments — averaging $28.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$554
  • AstraZeneca$306
  • Novo Nordisk$270
  • Inspire Medical Systems, Inc.$135
  • Madrigal Pharmaceuticals$123
  • AbbVie$122
  • plus $517 from 10 others

What the payments were for

  • Food & beverage$2,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,029 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Medicare billing

Part B allowed, 2024
$8,852
Medicare patients
94
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levocetirizine Dihydrochloride40$488
Rosuvastatin Calcium26$266
Pantoprazole Sodium15$261
Fluticasone Propionate27$258
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$210
Atorvastatin Calcium17$171
Gabapentin15$123
Losartan Potassium12$94
Pravastatin Sodium17$87
Alendronate Sodium18$82
Amlodipine Besylate20$61
Azithromycin13$46
Trazodone Hcl11$28

Paid to pharmacies, not to this prescriber.

Other family in Harvey

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →